...
首页> 外文期刊>Medicine. >TNF-α Antagonist Use and Risk of Hospitalization for Infection in a National Cohort of Veterans With Rheumatoid Arthritis
【24h】

TNF-α Antagonist Use and Risk of Hospitalization for Infection in a National Cohort of Veterans With Rheumatoid Arthritis

机译:TNF-α拮抗剂的使用和在风湿性关节炎国家退伍军人队列中住院感染的风险

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Medications used to treat rheumatoid arthritis (RA) may confer an increased risk of infection. We conducted a retrospective cohort study of veterans with RA followed in the United States Department of Veterans Affairs health care system from October 1998 through September 2005. Risk of hospitalization for infection associated with tumor necrosis factor (TNF)-α antagonists therapy was measured using an extension of Cox proportional hazards regression, adjusting for demographic characteristics, comorbid illnesses, and other medications used to treat RA. A total of 20,814 patients met inclusion criteria, including 3796 patients who received infliximab, etanercept, or adalimumab. Among the study cohort, 1465 patients (7.0%) were hospitalized at least once for infection. There were 1889 hospitalizations for infection. The most common hospitalized infections were pneumonia, bronchitis, and cellulitis. Age and several comorbid medical conditions were associated with hospitalization for infection. Prednisone (hazard ratio [HR], 2.14; 95% confidence interval [CI], 1.88-2.43) and TNF-α antagonist use (HR, 1.24; 95% CI, 1.02-1.50) were associated with hospitalization for infection, while the use of disease-modifying antirheumatic drugs (DMARDs) other than TNF-α antagonists was not. Compared to etanercept, infliximab was associated with risk for hospitalization for infection (HR, 1.51; 95% CI, 1.14-2.00), while adalimumab use was not (HR, 0.95; 95% CI, 0.68-1.33). In all treatment groups, rate of hospitalization for infection was highest in the first 8 months of therapy. We conclude that patients with RA who are treated with TNF-α antagonists are at higher risk for hospitalization for infection than those treated with other DMARDs. Prednisone use is also a risk factor for hospitalization for infection. Abbreviations: CI = confidence interval, DMARD = disease-modifying antirheumatic drug, HFI = hospitalization for infection, HR = hazard ratio, ICD-9-CM = International Classification of Diseases, Version 9, Clinical Modification, NHDS = National Hospital Discharge Survey, RA = rheumatoid arthritis, TNF-α = tumor necrosis factor-α, VA = Veterans Affairs.
机译:用于治疗类风湿关节炎(RA)的药物可能会增加感染的风险。我们从1998年10月至2005年9月在美国退伍军人事务卫生保健系统中对退伍军人进行了RA回顾性队列研究。使用肿瘤坏死因子(TNF)-α拮抗剂治疗相关感染的住院风险通过扩展Cox比例风险回归,调整人口统计学特征,合并症和其他用于治疗RA的药物。总共20,814名患者符合入选标准,其中3,796例接受了英夫利昔单抗,依那西普或阿达木单抗的患者。在该研究队列中,至少有1465名患者(7.0%)因感染而住院。有1889人因感染住院。最常见的住院感染是肺炎,支气管炎和蜂窝织炎。年龄和几种合并症与感染住院有关。泼尼松(危险比[HR]为2.14; 95%置信区间[CI]为1.88-2.43)和TNF-α拮抗剂的使用(HR为1.24; 95%CI为1.02-1.50)与感染住院有关,而没有使用除TNF-α拮抗剂以外的改善疾病的抗风湿药(DMARD)。与依那西普相比,英夫利昔单抗与住院风险相关(HR,1.51; 95%CI,1.14-2.00),而未使用阿达木单抗(HR,0.95; 95%CI,0.68-1.33)。在所有治疗组中,感染的住院率在治疗的前8个月中最高。我们得出结论,接受TNF-α拮抗剂治疗的RA患者比接受其他DMARDs治疗的患者住院感染的风险更高。泼尼松的使用也是感染住院的危险因素。缩写:CI =置信区间,DMARD =改变疾病的抗风湿药,HFI =感染住院,HR =危险比,ICD-9-CM =国际疾病分类,第9版,临床修改,NHDS =国家医院出院调查, RA =类风湿关节炎,TNF-α=肿瘤坏死因子-α,VA =退伍军人事务。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号